ProCE Banner Activity


A New Era of Early-Stage Cancer Care: Clinical Impact of Pathologic Response to Immunotherapy


Watch this on-demand webcast from a live AACR satellite symposium to learn from an expert pathologist and a clinical oncologist about the use of pathologic response to neoadjuvant therapies, including using pathologic response as a clinical trial endpoint for immunotherapy.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: May 03, 2023

Expiration: May 02, 2024

No longer available for credit.



Patrick Forde

Patrick Forde, MBBCh

Director, Thoracic Oncology Research Program
Oncology Department
Johns Hopkins University
Baltimore, Maryland

Michael T. Tetzlaff

Michael T. Tetzlaff, MD, PhD

Professor of Pathology
Division of Dermatopathology
University of California at San Francisco
San Francisco, California

Provided by

This activity is provided by Clinical Care Options, LLC

ProCE Banner


This activity is supported by educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Target Audience

This program is intended for pathologists, oncologists, pulmonologists, surgeons, clinical investigators, and other healthcare professionals involved in the treatment of patients with solid tumors.

Program Learning Goal

The goal of this program is to improve the knowledge, competence, and performance of learners in the optimal application of pathologic response as a marker to guide therapy and assess clinical trial data with the use of immunotherapy in the neoadjuvant setting.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss with colleagues the differences between pathologic response scoring systems for neoadjuvant chemotherapy vs immunotherapy and their use as a surrogate endpoint for survival when designing or interpreting clinical trials

  • Utilize immune-related pathologic response scoring systems to assess pathologic response in patients undergoing neoadjuvant immunotherapy, considering the differences between response to chemotherapy vs immune checkpoint inhibitor‒based therapy

  • Plan neoadjuvant therapeutic strategies using immunotherapies for appropriate patients with early-stage cancer

  • Develop therapeutic strategies for patients who do not achieve a pathologic complete response to neoadjuvant immunotherapy using available clinical evidence and expert guidance


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Patrick Forde, MBBCh

Director, Thoracic Oncology Research Program
Oncology Department
Johns Hopkins University
Baltimore, Maryland

Patrick Forde, MBBCh: consultant/advisor/speaker: Amgen, AstraZeneca, Bristol-Myers Squibb, Daichii Sankyo, F Star, Genentech, Gritstone, G1 Therapeutics, Iteos, Janssen, Novartis, Regeneron, Sanofi, Surface; researcher (paid to institution): AstraZeneca, Biontech, Bristol-Myers Squibb, Regeneron.

Michael T. Tetzlaff, MD, PhD

Professor of Pathology
Division of Dermatopathology
University of California at San Francisco
San Francisco, California

Michael Tetzlaff, MD, PhD, has no relevant financial relationships to disclose.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from May 03, 2023, through May 02, 2024:

  1.  Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.